The biology of E-selectin ligands in leukemogenesis.

CD44 E-selectin E-selectin ligand HCELL Hematopoiesis Hematopoietic niche Leukemia SLeX Sialyl Lewis X Vascular niche

Journal

Advances in cancer research
ISSN: 2162-5557
Titre abrégé: Adv Cancer Res
Pays: United States
ID NLM: 0370416

Informations de publication

Date de publication:
2023
Historique:
entrez: 1 2 2023
pubmed: 2 2 2023
medline: 4 2 2023
Statut: ppublish

Résumé

Both the cascade whereby a blood-borne cell enters a tissue and the anchoring of hematopoietic stem/progenitor cells (HSPCs) within bone marrow critically pivots on cell-cell interactions mediated by E-selectin binding to its canonical carbohydrate ligand, the tetrasaccharide termed "sialylated Lewis X" (sLeX). E-selectin, a member of the selectin class of adhesion molecules that is exclusively expressed by vascular endothelium, engages sLeX-bearing glycoconjugates that adorn mature leukocytes and HSPCs, as well as malignant cells, thereby permitting these cells to extravasate into various tissues. E-selectin expression is induced on microvascular endothelial cells within inflammatory loci at all tissues. However, conspicuously, E-selectin is constitutively expressed within microvessels in skin and marrow and, additionally, is inducibly expressed at these sites. Within the marrow, E-selectin receptor/ligand interactions promote lodgment of HSPCs and their malignant counterparts within hematopoietic growth-promoting microenvironments, collectively known as "vascular niches". Indeed, E-selectin receptor/ligand interactions have been reported to regulate both hematopoietic stem, and leukemic, cell proliferative dynamics. As such, signaling induced via engagement of E-selectin ligands is gaining interest as a critical mediator of homeostatic and malignant hematopoiesis, and this review will present current perspectives on the glycoconjugates mediating E-selectin receptor/ligand interactions and their currently defined role(s) in leukemogenesis.

Identifiants

pubmed: 36725110
pii: S0065-230X(22)00072-0
doi: 10.1016/bs.acr.2022.07.001
pii:
doi:

Substances chimiques

E-Selectin 0
Glycoconjugates 0
Ligands 0

Types de publication

Review Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-250

Subventions

Organisme : NCI NIH HHS
ID : U01 CA225730
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL107146
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Evan Ales (E)

Department of Translational Medicine & The Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.

Robert Sackstein (R)

Department of Translational Medicine & The Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States. Electronic address: sackstein@fiu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH